Filing Analysis
Insight Molecular Diagnostics Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 11, 2026. Shareholders elected four directors, ratified the appointment of CBIZ CPAs P.C. as independent auditors, approved executive compensation, and approved an expansion of the company's equity incentive plan.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with 74.19% of voting power represented.
- Shareholders approved an increase of 1,750,000 shares to the Amended and Restated 2018 Equity Incentive Plan, bringing the total authorized shares under the plan to 5,550,000.
- Elected directors for the 2027 term: Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation for the year ended December 31, 2025, was approved on a non-binding advisory basis.
Insight Molecular Diagnostics Inc. filed an 8-K/A to amend a previous filing, correctly reclassifying the announcement of a Specimen Collection Agreement with Quest Diagnostics from Item 1.01 to Item 8.01. The agreement pertains to specimen collection services for the Company's GraftAssureCore™ dd-cfDNA blood test.
📋 Key Facts
- The company entered into a Specimen Collection Agreement with Quest Diagnostics.
- The agreement supports the GraftAssureCore™ test, a PCR-based measurement platform for donor-derived cell free DNA (dd-cfDNA).
- This filing is an amendment (8-K/A) dated May 13, 2026, correcting a filing from February 20, 2026.
Insight Molecular Diagnostics Inc. (IMDX) announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results cover the three-month period ended March 31, 2026
- The report was filed on May 13, 2026
- Information was furnished under Item 2.02 and is not deemed 'filed' for Section 18 liability purposes
- The company is listed on The Nasdaq Stock Market LLC under the ticker IMDX
Insight Molecular Diagnostics Inc. filed this 8-K to correct a clerical error in its Third Amended and Restated Bylaws previously filed with its 2025 Annual Report. The original exhibit inadvertently included incorrect shareholder voting provisions that were not part of the actual bylaws.
🚩 Red Flags
- Clerical error in a primary governing document (Bylaws) suggests potential lapses in administrative oversight or legal review of SEC filings.
📋 Key Facts
- The company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 26, 2026.
- Exhibit 3.5 of the 10-K contained a clerical error regarding shareholder voting provisions.
- The company is filing the corrected Third Amended and Restated Bylaws as Exhibit 3.1 to this 8-K.
- The correction does not change any other disclosures contained in the previously filed Form 10-K.
Insight Molecular Diagnostics Inc. (IMDX) furnished its financial results for the quarter and fiscal year ended December 31, 2025, via a press release on March 26, 2026.
📋 Key Facts
- Announced financial results for the "three and twelve months ended December 31, 2025"
- Press release furnished as Exhibit 99.1
- Reported on March 26, 2026, under Item 2.02 Results of Operations and Financial Condition
Insight Molecular Diagnostics Inc. (IMDX) entered into a Specimen Collection Agreement with Quest Diagnostics for its GraftAssureCore™ blood test. The agreement includes a provision for both parties to negotiate in good faith for additional rights to the GraftAssure technology.
📋 Key Facts
- Agreement entered on February 20, 2026, with Quest Diagnostics Incorporated.
- Quest will provide specimen collection services for IMDX's GraftAssureCore™ test, which measures donor-derived cell free DNA (dd-cfDNA).
- IMDX will pay fees to Quest for services rendered.
- The parties agreed to a specified period to negotiate additional rights to the GraftAssure technology.
- The full text of the agreement was not included but is expected in a future filing.